DOCSLIB.ORG

Americans for Safe Access

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Americans for Safe Access Americans for Safe Access ACTIVIST NEWSLETTER Defending Patients’ Access to Medical Marijuana AUGUST 2015 Volume 10, Issue 8 Congressmen Call for Probe of Justice Department Members of Congress want an investi - DOJ officials have said they can prosecute indi - end all federal prose - gation of federal prosecutors who viduals who are part of state medical cannabis cution of state-quali - continue to pursue medical cannabis programs and pursue civil asset forfeiture fied patients and cases despite restrictions placed on them last against them because that is not interfering in providers because year. Reps. Dana Rohrabacher (R-CA) and Sam implementing state medical marijuana laws. "the implementa - Farr (D-CA) sent a letter on July 30 to DOJ tion of state law is Inspector General Michael Horowitz, asking Reps. Rohrabacher and Farr authored the Reps. Rohrabacher and Farr carried out by indi - him “to investigate potential violations of the amendment to the 2015 DOJ budget bill viduals and business - Anti-Deficiency Act by the Department with intended to stop enforcement actions against es as the state authorizes them to do." regard to its prosecution and other enforce - anyone participating in state medical cannabis ment actions against persons and businesses programs. Their letter states debate on their Prosecutors in California and Washington State conducting legitimate medical marijuana activ - amendment made clear that supporters and have refused to back down from several high- ities under state law." opponents alike understood it was intended to profile cases, asking for prison time for the Kettle Falls Five, members of a family patient CARERS Act Gains Powerful Co-Sponsors co-op in Washington State, as well as a dispen - sary operator in California, while pursuing The CARERS Act, the first comprehen - Rand Paul (R-KY) asset forfeiture against the building leased by sive medical cannabis legislation to be and the junior sena - a dispensary in Oakland, California. In the let - considered by Congress, is up to 15 tor from New York, ter, Rohrabacher and Farr write that such cases bipartisan co-sponsors in the Senate, now that Kirsten Gillibrand “are all instances of DOJ expending dollars it two influential senior senators have added (D). Other co-spon - does not have the legal authority to spend." their names. Chuck Schumer of New York and sors include senators Barbara Mikulski of Maryland each became co- Sens. Mikulski and Schumer from the states of sponsors of SB 683 at the end of July. California, Colorado, 16 MONTHS FOR KETTLE Hawaii, Maine, Nevada, New Mexico, Oregon FALLS FIVE DEFENDANT Sen. Mikulski is the ranking member of the and Wisconsin. The bill is currently in the hands powerful Appropriations Committee and was of the Senate Judiciary Committee, but com - The first prison sentence has been instrumental in preserving the Rohrabacher- mittee chair Charles Grassley (R-IA) has yet to handed down in the case of the Farr Amendment that limits federal interfer - set hearings. “Kettle Falls Five,” the group of quali - ence in state medical cannabis laws. Sen. fied patients in Eastern Washington who were Schumer is the third ranking Democrat in the “Medical marijuana is the only recourse for indicted on federal charges.District Court Senate with a reputation as an ardent support - many in New York and across the country who Judge Thomas O. Rice sentenced Jason Zucker er of the War on Drugs. are in a great deal of pain,” Sen. Schumer said to 16 months in federal prison, but he remains in a statement. “It is only humane and fair that free on bond pending appeal. The legislation authored by Sen. Cory Booker they have access to the treatment they need (D-NJ) was originally co-sponsored by Sen. when prescribed by a doctor.” Zucker, 39, second from left in the photo at right, was the only one of the group to plead guilty. He accepted a last-minute deal with New Medical Cannabis Laws in Washington prosecutors to avoid the 20-year mandatory Several medical cannabis bills were ties than non-medical consumers. Households minimum sentence he faced if convicted. passed by the Washington State legis - will now be limited to the cultivation of 15 lature or went into effect last month. plants. To qualify for the additional amounts Charges against Larry Harvey, the 71-year-old The measures were part of policymakers’ and protections, qualifying patients must reg - patriarch of the family who was ASA’s Lobbyist attempt to harmonize the state’s existing med - ister in the state’s new voluntary database, of the Year, were dropped in March just before ical cannabis program with the new law that which law enforcement will be able to access trial because he has Stage 4 pancreatic cancer. allows anyone who is at least 21 years of age to confirm registrations. This bill also expand - At trial, Zucker testified against Harvey’s wife, to purchase and use cannabis. Among the ed the qualifying medical conditions to include Rhonda Firestack-Harvey, and her son and changes is the name of the regulatory agency. post traumatic stress disorder and traumatic daughter-in law, Rolland and Michelle Gregg, The state Liquor Control Board keeps its 81- brain injuries but creates restrictions that will but made clear that their cannabis cultivation year-old acronym but the ‘C’ now stands for shut down many of the state’s existing medical operation was a co-op in which he and the ‘Cannabis,’ as in Liquor and Cannabis Board. cannabis businesses. The bill also specifies that four family members shared the medicine. qualifying patients between the ages of 18 Of the bills, the most wide-reaching is SB 5052, and 21 will be able to purchase cannabis at The jury acquitted Firestack-Harvey and the which brings much of the state’s largely unreg - retail locations with a medical endorsement. Greggs of four out of five charges and rejected ulated medical cannabis operations under the the government’s claim that they had cultivat - umbrella of the new adult-use regulations State support for cannabis research was creat - ed more than 100 plants. The remaining three while allowing qualified patients to continue ed by SB 5121, which establishes a licensing defendants are scheduled to be sentenced on personal cultivation and possess larger quanti - continues, page 2 October 2 in Spokane Americans for Safe Access • 1806 Vernon Street NW • Washington, D.C. 20009 202-857-4272 • [email protected] • www.AmericansForSafeAccess.org New York Officials Announce Five Licensees In what Health Commissioner Dr. LLC, Empire State Health Solutions, Etain LLC, AMERICANS FOR Howard A. Zucker called “a major PharmaCann LLC. Each will have a single culti - milestone” for the state’s medical vation facility and four retail dispensing loca - SAFE ACCESS cannabis program, New York has announced tions in different cities. facebook.com/SafeAccessNow five companies that will be licensed to operate twitter.com/SafeAccess dispensaries and cultivation facilities. Forty- The firms selected are to have medical three had applied. cannabis products, which will be subject to a 7 youtube.com/SafeAccess percent tax, available by Jan. 1. The Phone: 510-251-1856 The five selected firms for the state are Compassionate Care Act was signed into law Fax: 510-251-2036 Bloomfield Industries Inc., Columbia Care NY by Gov. Andrew Cuomo last July. [email protected] First Nevada Cannabis Dispensary Opens On the last day of July, Nevada’s first begin serving patients. Israel to Expand Program, medical cannabis dispensary opened Offer Cannabis in Pharmacies in Sparks, just a few miles east of In the 15 years since state voters okayed med - Reno. Of the two dozen states that allow med - ical use, registered patients or their caregivers Long a leader in cannabis research, Israel will ical cannabis use, Nevada is one of the few could only access medical cannabis by growing soon make medical cannabis available that recognizes patients who are registered to up to 12 plants themselves, which they may through pharmacies in the country and use cannabis in their home state. continue to do. expand the number of physicians who are authorized to prescribe it. The announcement Since the state legislature adopted rules for Nevada's new distribution regulations include was made in the Knesset by Israel’s deputy distribution operations two years ago, 66 "seed-to-sale" tracking similar to Colorado’s. health minister, Yaakov Litzman, head of an dispensary licenses have been issued. The The state Department of Agriculture is finaliz - ultra-orthodox party. Before the Health Sparks City Council approved dispensaries ing a testing process that will screen for dozens Ministry can license more growers to supply last year, with Silver State Relief the first to of common pesticides. the pharmacies, the country’s Supreme Court must sign off. ACTION ALERT: Five Things to Do this Summer The 22,000 Israelis who are authorized to use medical cannabis must acquire it directly from 1. Host or Attend an Educational Session government-authorized farms. Allowing more Three workshop sessions are available in ASA's Truth About Medical Marijuana physicians to prescribe the medicine is intend - Educational Series. We’ll send you everything you need for a successful meeting, ed to eliminate the wait list that is currently a including a video, engagement materials, and a survey. barrier to access. Israel has more medical users per capita than any other country. 2. Engage your Senators about the CARERS Act Constituents are 6x more effective than lobbyists. Urge your senators to support the CARERS Act, the comprehensive federal medical cannabis legislation. Visit their local Italy’s Army Cultivating Senate office or take five minutes to call and demand their support for patients.
Load more

Recommended publications
  • 2017 Global Drug Survey
    Prepared by the GDS Core Research Team Dr Adam Winstock, Dr Monica Barratt, Dr Jason Ferris & Dr Larissa Maier Global overview and highlights N > 115,000 Global Drug Survey GDS2017 © Not to be reproduced without authors permission Hi everyone On behalf of the GDS Core Research Team and everyone of our amazing international network partners and supportive media organisations we’d like to share our headline report deck. I know it won’t have everything that everyone wants but we are hopeful it will give people an idea of how the world of drugs is changing and highlight some of the key things that we think people can better engage with to keep themselves and those they care for safe. Once we cleaned the data from 150,000 people we chose to use data from just under 120,000 people this year for these reports. We have data reports addressing 18 different areas for over 25 countries. We can only share a fraction of what we have here on the site. However, we are very open to sharing the other findings we have and would ask researchers and public health groups to contact us so we can discuss funding and collaboration. We have almost completed designing GDS2018 so that we can start piloting early and give countries where we have not yet found friends to reach out to us. We particularly want to hear from people in Japan, Eastern Europe, Africa and the Middle East. Dr Adam R Winstock Founder and CEO Global Drug Survey Consultant Psychiatrist and Addiction Medicine Specialist Global Drug Survey GDS2017 © Not to be reproduced without authors permission We think this will be interesting.
    [Show full text]
  • Access to Medicinal Cannabis: Meeting Patient Needs
    Access to medicinal cannabis: meeting patient needs All-Party Parliamentary Group for Drug Policy Reform Inquiry Report “The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition.” Constitution of the World Health Organisation drawn up in 1946 in conformity with the Charter of the United Nations Foreword For six years, the All-Party Parliamentary Group for Drug Policy Reform has worked for an end to the “war on drugs” driven by the USA and supported by the UN. In our “Guidance on Interpreting the UN Drugs Conventions”, we called for three major changes: 1. evidence-based drugs policy; 2. policy that genuinely promotes the health and welfare of mankind driven by human rights and public health values; 3. flexibility for Member States to develop drug policy within the UN Conventions based on our four “Guidance” principles. We have had meetings with the President of the UN Economic and Social Council (ECOSOC); the Executive Director of the UN Office on Drugs and Crime (UNODC); and the Deputy Secretary General of the UN. We have organised international meetings of Ministers and senior officials in Westminster and spoken at international meetings in New York, Brussels and Cartagena, Colombia. At the UN General Assembly Special Session (UNGASS) held in April 2016, we witnessed both the USA and the UN leadership reject a moralistic and prohibitionist approach to the global drug problem. Instead, the UN and US leaders called for all our proposed changes to global drugs policy.
    [Show full text]
  • Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations
    molecules Article Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations Alberto Ramella 1, Gabriella Roda 2, Radmila Pavlovic 3,*, Michele Dei Cas 4 , Eleonora Casagni 2, Giacomo Mosconi 3, Francisco Cecati 5, Paola Minghetti 2 and Carlo Grizzetti 6 1 Farmacia Dott.ri Giuliana e Alberto Ramella–SAS, Via A. Diaz 1, 21021 Angera (VA), Italy; [email protected] 2 Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via L. Mangiagalli 25, 20133 Milan, Italy; [email protected] (G.R.); [email protected] (E.C.); [email protected] (P.M.) 3 Department of Health, Animal Science and Food Safety, University of Milan, 20133 Milan, Italy; [email protected] 4 Department of Health Sciences, Università degli Studi di Milano, Via A.di Rudinì 8, 20142 Milan, Italy; [email protected] 5 INTEQUI-CONICET, Faculty of Chemistry, Biochemistry and Pharmacy, National University of San Luis, Almirante Brown 1455, San Luis CP 5700, Argentina; [email protected] 6 S.S.D. Cure Palliative e Terapia del Dolore, Ospedale di Circolo–Fondazione Macchi, ASST Sette Laghi, Viale L. Borri 57, 21100 Varese, Italy; [email protected] * Correspondence: [email protected] Academic Editor: Maria Carla Marcotullio Received: 2 June 2020; Accepted: 29 June 2020; Published: 30 June 2020 Abstract: The feasibility of the use of two lipid sources and their impact on the cannabinoid profile, terpene fingerprint, and degradation products in medical cannabis oil preparations during 3 months of refrigerated storage time were investigated. LCHRMS-Orbitrap® and HS-SPME coupled to GC-MS for the investigation of targeted and untargeted cannabinoids, terpenes, and lipid degradation products in Bedrocan® and Bediol® macerated oils were used as analytical approaches.
    [Show full text]
  • PTW 1-19 INH 190318 V07.Indd
    Herausgegeben von der Schweizer Charta für Psychotherapie in der Assoziation Schweizer Psychotherapeutinnen und Psychotherapeuten Psychotherapie-Wissenschaft Science Psychothérapeutique WWW.PSYCHOTHERAPIE-WISSENSCHAFT.INFO Kultur, Religion und Psychotherapie Culture, religion et psychothérapie Cultura, religione e psicoterapia 9 . Jahrgang Heft 1 / 2019 Herausgegeben von Mario Schlegel und Nicola Gianinazzi ISSN 1664-9583 Psychosozial-Verlag Impressum Psychotherapie-Wissenschaft Abo-Verwaltung ISSN 1664-9583 (Print-Version) Psychosozial-Verlag ISSN 1664-9591 (digitale Version) [email protected] 9. Jahrgang Heft 1/2019 https://doi.org/10.30820/1664-9583-2019-1 Bezugsgebühren Jahresabonnement 44,90 € (zzgl. Versand) Herausgeber Einzelheft 24,90 € (zzgl. Versand) Schweizer Charta für Psychotherapie in der Assoziation Studierende erhalten gegen Nachweis 25 % Rabatt. Schweizer Psychotherapeutinnen und Psychotherapeuten Das Abonnement verlängert sich um jeweils ein Jahr, sofern nicht eine Geschäftsstelle ASP Abbestellung bis acht Wochen vor Ende des Bezugszeitraums erfolgt. Riedtlistr. 8 ASP-Mitglieder wenden sich wegen des Abonnements bitte CH-8006 Zürich direkt an die ASP. Tel. +41 43 268 93 00 www. psychotherapie.ch Anzeigen Anfragen zu Anzeigen bitte an den Verlag: Redaktion [email protected] Rosmarie Barwinski, Zürich Es gelten die Preise der auf www.psychosozial-verlag.de Nicola Gianinazzi, Lugano einsehbaren Mediadaten. Astrid Grossert, Basel ASP-Mitglieder wenden sich bitte direkt an die Redaktion. Margit Koemeda, Zürich Mario Schlegel, Zürich Digitale Version Peter Schulthess, Zürich Die Zeitschrift Psychotherapie-Wissenschaft ist auch online einsehbar: www.psychotherapie-wissenschaft.info [email protected] www.psychotherapie-wissenschaft.info Hinweise für AutorInnen befinden sich auf der Homepage der Zeitschrift: www.psychotherapie-wissenschaft.info Die Beiträge dieser Zeitschrift sind unter der Creative Commons Attribution-NonCommercial-NoDerivs 3.0 DE Lizenz lizensiert.
    [Show full text]
  • EMCDDA Cannabis Reader
    ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
    [Show full text]
  • MEDICAL CANNABIS in EUROPE: the Markets & Opportunities SECOND EDITION
    MEDICAL CANNABIS IN EUROPE: The Markets & Opportunities SECOND EDITION In-depth look at key European markets and the regulations companies need to understand to tap these revenue opportunities © 2020 Anne Holland Ventures Inc. All Rights Reserved Medical cannabis for German patients We purchase and import EU-GMP medical cannabis into Germany and sell to pharmaceutical wholesalers who supply to pharmacists Subscribe to our newsletter at amp-eu.com/learnmore Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl TABLE OF CONTENTS WLECOME LETTER 5 EU MARKET AT A GLANCE 9 GERMANY 14 ITALY 43 THE NETHERLANDS 55 DENMARK 65 CZECH REPUBLIC 74 AUSTRIA AND SWITZERLAND 78 OTHER SMALL MARKETS 80 3 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. RESEARCH DRIVEN LEDs for Compact Plants with High THC/CBD Outputs UV-A Enriched Spectrum for Increased Cannabinoid Production GACP/GMP Facility Suitable Since 2009 we have been committed to creating the best LED grow lights on the market so as to enable growers to increase yields, quality and energy savings. With the largest patent portfolio in the cannabis lighting industry, we are the pioneers of the high quality horticultural LED solutions. 31% 16% 28% more more total more compact plants cannabinoid flowers yield ...than with HPS. 7% 6% 4% more more total more compact plants cannabinoid THC yield ...than with competitor’s LEDs.
    [Show full text]
  • ANALYSIS of EXPERIENCE COUNTRIES of the WORLD on LEGALIZATION of MEDICAL CANNABIS Nemchenko A
    Фізіологія, валеологія, медицина: сучасний стан та перспективи розвитку : тези доповідей Всеукраїнської науково-практичної інтернет-конференції (06 квітня 2021 р.) ANALYSIS OF EXPERIENCE COUNTRIES OF THE WORLD ON LEGALIZATION OF MEDICAL CANNABIS Nemchenko A. S., Kurylenko Y. E., Kuzmenko A. A. National University of Pharmacy, Kharkiv, Ukraine [email protected] Introduction. The WHO estimates that 1.2 billion people worldwide suffer from diseases in which medical cannabis has therapeutic value. The global world cannabis market (regulated and illegal) is estimated at $ 344 billion. USA. The five largest regional markets include: Asia ($ 132.9 billion), North America ($ 85.6 billion), Europe ($ 68.5 billion), Africa (37, $ 3 billion), Latin America ($ 9.8 billion). That is, the development of the cannabis industry is promising in terms of state regulation by the authorities in order to fill the budget and economic development of countries. The purpose of the study is to analyze the experience of countries around the world that have already legalized medical cannabis. Research materials: data from the official websites of the WHO, "American medical marijuana association", "European medicinal cannabis association". Results and discussion. For the analysis, we selected countries with a high level of GDP which have successfully legalized medical cannabis. The analysis found that in the United States, the majority of the 50 states, namely 36, legalized cannabis for medical use. From a historical point of view, in 1985, 23% of the total population consumed this substance. In 2015, cannabis consumption increased to 48%, and in 2018, 62% of the US population used cannabis. In 2019, consumption decreased by 15%.
    [Show full text]
  • Cannabis Control in Europe
    EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 OLUME I V Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA's partners, any EU Member State or any agency or institution of the European Union or European Communities. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu). Europe Direct is a service to help you find answers to your questions about the European Union Freephone number: 00 800 6 7 8 9 10 11 This publication should be referenced as: EMCDDA (2008), A cannabis reader: global issues and local experiences, Monograph series 8, Volume 1, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. References to chapters in this monograph should include, where relevant, references to the authors of each chapter, together with a reference to the wider publication. For example: Corrigan, D. (2008), ‘The pharmacology of cannabis: issues for understanding its use’, in: A cannabis reader: global issues and local experiences, Monograph series 8, Volume 1, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. The publication is available on the Internet at: http://www.emcdda.europa.eu/publications/monographs/cannabis Cataloguing data can be found at the end of this publication.
    [Show full text]
  • Cannabis for Medical Use - a Scientific Review
    Cannabis for Medical Use - A Scientific Review 31 JANUARY 2017 Cannabis for Medical Use – A Scientific Review CONTENTS 1 EXECUTIVE SUMMARY 1 2 OVERVIEW OF HPRA REVIEW 2 3 BACKGROUND 6 4 MEDICINES AUTHORISATION IN IRELAND 7 5 CANNABIS AND ITS REGULATION IN IRELAND 8 6 MEDICAL USE OF CANNABIS 9 7 SUMMARY OF SCIENTIFIC DATA ON EFFECTIVENESS 13 8 SUMMARY OF SCIENTIFIC DATA ON SAFETY 16 9 CANNABIS MISUSE 18 10 INTERNATIONAL PROGRAMMES FOR CANNABIS ACCESS 18 11 CONCLUSIONS 21 APPENDIX 1 MINISTER OF HEALTH’S LETTER TO THE HPRA 27 APPENDIX 2 HPRA EXPERT WORKING GROUP ON CANNABIS FOR MEDICAL USE 28 APPENDIX 3 MEDICINES AUTHORISATION IN IRELAND 29 APPENDIX 4 MISUSE OF DRUGS FRAMEWORK RELATING TO CANNABIS 31 APPENDIX 5 FORMS OF CANNABIS AND CANNABINOIDS AND AUTHORISATION STATUS 34 APPENDIX 6 REVIEW OF EFFECTIVENESS AND SAFETY 35 APPENDIX 7 CLINICAL TRIALS 67 APPENDIX 8 SURVEY TO DETERMINE WORLDWIDE STATUS 70 APPENDIX 9 REFERENCES 78 Cannabis for Medical Use – A Scientific Review 1 EXECUTIVE SUMMARY The Health Products Regulatory Authority (HPRA) convened an expert working group to assist with its review of the potential medical use of cannabis, as requested by the Minister for Health. The key findings of the working group are: 1. To date there is an absence of scientific data demonstrating the effectiveness (efficacy) of cannabis products. The safety of cannabis as a medical treatment is not well characterised. In particular, there is insufficient information on its safety during long- term use for the treatment of chronic medical conditions, such as those for which there is a public interest.
    [Show full text]
  • The Annual 2018 Journal for Breeders and Producers of Plant Material
    The Annual 2018 Journal for breeders and producers of plant material Prophyta 2018.indd 1 17-04-18 09:28 inspections • Quality inspections • Import inspections • Plant Passport Naktuinbouw safeguards • Quality-plus systems • NAL / Naktuinbouw-Elite and promotes the quality, testing and research identity and health of • Health and quality testing horticultural propagating • Seed analysis • Diagnostic testing material • DNA tests • Disease resistance 1 testing registration, listing and plant breeders’ rights • DUS Testing for Plant Breeders’ Rights for agricultural and horticultural crops • Description of varieties education • Identity investigation • Regular workshops and training courses • In company workshops and training courses Naktuinbouw +31 (0)71 332 6262 [email protected] www.naktuinbouw.com prophyta annual 2017 Prophyta 2018.indd 2 17-04-18 09:28 Prophyta – The Annual 2018 A publication of the Prophyta Foundation in co-operation The Annual 2018 with Blue Bird Publishers Journal for breeders and producers of plant material editorial advisory board Theo Ruys, John van Ruiten and Jan Timmerman publisher/chief editor Monique Krinkels contributing editors Anke van den Hurk, Geert-Jan de Klerk, Radha Ranganathan, Marlies Reus, Fabiola Rivera, John van Ruiten, Jan Velema, Christiaan Weijts 4 In Short 22 the idealists cover photograph Dr. Gianpaolo Grassi 5 Editorial Sowing relief in Africa sub editor Mireille McNutt 3 6 world seed congress 2018 25 seed drying graphic design Marcel Bakker, De Ontwerperij Innovative atmosphere offers Energy efficiency becomes more printed by Global Printing important address Blue Bird Publishers fertile ground for seed industry vof, Jan Kostelijklaan 16 27 half a century of seed enhancement 1981 cg Velsen-Zuid Innovation never stops the Netherlands phone +31 (0)255 521 852 28 sow to grow fax +31 (0)847 510 694 Let’s play plant breeder [email protected] www.bluebirdpublishers.com prophyta foundation [email protected] www.prophyta.org © 2018 All rights reserved.
    [Show full text]
  • BULLETIN on NARCOTICS—Volume LVIII, Nos
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org BULLETIN ON NARCOTICS—Volume LVIII, Nos. 1 and 2, 2006 LVIII, BULLETIN ON NARCOTICS—Volume Volume LVIII, Nos. 1 and 2, 2006 Review of the world cannabis situation FOR UNITED NATIONS USE ONLY United Nations publication ISBN 978-92-1-148228-7 ISSN 0007-523X *0781746*Printed in Austria Sales No. E.08.XI.10 V.07-81746—April 2008—2,005 UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna BULLETIN ON NARCOTICS Volume LVIII, Nos.1 and 2, 2006 Review of the world cannabis situation UNITED NATIONS New York, 2008 UNITED NATIONS PUBLICATION Sales No. E.08.XI.10 ISBN 978-92-1-148228-7 ISSN 0007-523X Sandeep Chawla, Editor, Suzanne Kunnen, Editorial Assistant United Nations Offi ce on Drugs and Crime Vienna International Centre P.O. Box 500 1400 Vienna, Austria Telephone: (+43-1) 26060-5799 Fax: (+43-1) 26060-5866 The Bulletin on Narcotics is available on the World Wide Web at www.unodc.org/unodc/en/bulletin_on_narcotics.html. Views expressed in signed articles published in the Bulletin are those of the authors and do not necessarily refl ect those of the United Nations Secretariat. The designations employed and the presentation of the material in the present publication do not imply the expression of any opinion whatsoever on the part of the Secretariat concerning the legal status of any country, territory, city or area, or its authorities, or concerning the delimitation of any frontiers or boundaries.
    [Show full text]
  • Marijuana Legalization and Taxation: Approaches of States from the Perspective of Public Finances
    FACULTY OF ECONOMICS AND ADMINISTRATION Marijuana legalization and taxation: approaches of states from the perspective of public finances. Diploma Thesis SERENA IGLINA Supervisor: Robert Jahoda Public Finance and Economics Brno 2021 MARIJUANA LEGALIZATION AND TAXATION: APPROACHES OF STATES FROM THE PERSPECTIVE OF PUBLIC FINANCES. Bibliographic record Author: Serena Iglina Faculty of Economics and Administration Masaryk University Department of Public Economics Title of Thesis: Marijuana legalization and taxation: Approaches of states from the perspective of public finances. Degree Programme: Public Finance and Economics Field of Study: Public Finance and Economics Supervisor: Robert Jahoda Year: 2021 Number of Pages: 81 Keywords: Marijuana, taxation, legalization, prohibition, revenue, drug consumption, economic cost-benefit analysis TABLE OF CONTENT Abstract The very long political debate, the growing amount of economic data and new scientific studies on drugs have brought to the attention the academic literature on the economic consequences linked to prohibition and legalization of drugs. This study aims to provide an economic and political analysis starting from the analysis of historical data concerning prohibition and legalization. Moreover, it aims to estimate the limits imposed by the so- called anti-drug policies, which have long hindered the growth and development of emerging and significant sectors from a mainly economic but also political and social point of view. The economic and social consequences related to alcohol prohibition in the U.S.A. are highlighted to be able to draw up a cost-benefit analysis that allows a comparison between a market in which consumption is prohibited with one that rules its consumption and sale. Then, drug consumption trends - in particular cannabis - are analyzed both in a context of legality and in an illicit market.
    [Show full text]